The molecular pathogenesis of acute promyelocytic leukaemia: Implications for the clinical management of the disease

Blood Reviews

Volumn 17, Issue 2, 2003, Pages 71-97

  Mistry, Anita R ^a   Pedersen, Eva W ^a   Solomon, Ellen ^a   Grimwade, David ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Acute promyelocytic leukemia (APL); Arsenic trioxide (ATRA)

Indexed keywords

ARSENIC TRIOXIDE; RETINOIC ACID RECEPTOR;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MATURATION; CHROMOSOME REARRANGEMENT; GENE REPRESSION; GENE TARGETING; GENETIC CODE; HUMAN; MOLECULAR GENETICS; MOLECULAR PROBE; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

EID: 0037409182     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(02)00075-9     Document Type: Article

References (265)

1. Alcalay M, Zangrilli D, Fagioli M et al. Expression pattern of the RARα-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 4840-4844.
2. Borrow J, Solomon E. Molecular analysis of the t(15;17) translocation in acute promyelocytic leukaemia. Baillieres Clin Haematol 1992; 5: 833-856.
3. Grimwade D, Biondi A, Mozziconacci MJ et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies. Blood 2000; 96: 1297-1308.
4. Rowley JD, Golomb HM, Dougherty C. 15/17 Translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977; 1: 549-550.
5. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76: 827-841.
6. Chen Z, Brand NJ, Chen A et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993; 12: 1161-1167.
7. Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 1997; 17: 109-113.
8. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosminretinoic acid receptor fusion. Blood 1996; 87: 882-886.
9. Arnould C, Philippe C, Bourdon V, Gr goire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukaemia. Hum Mol Genet 1999; 8: 1741-1749.
10. Neves H, Ramos C, da Silva MG, Parreira A, Parreira L. The nuclear topography of ABL, BCR, PML, and RARα genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. Blood 1999; 93: 1197-1207.
11. Yoshida H, Naoe T, Fukutani H, Kiyoi H, Kubo K, Ohno R. Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: sequence non-specific recombination between the PML and RARA genes within identical short stretches. Genes Chromosomes Cancer 1995; 12: 37-44.
12. Brendel C, Neubauer A. Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions. Leukemia 2000; 14: 1711-1717.
13. Leid M, Kastner P, Chambon P. Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem Sci 1992; 17: 427-433.
14. Stunnenberg HG. Mechanisms of transactivation by retinoic acid receptors. Bioessays 1993; 15: 309-315.
15. Laudet V, Hanni C, Coll J, Catzeflis F, Stehelin D. Evolution of the nuclear receptor gene superfamily. EMBO J 1992; 11: 1003-1013.
16. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992; 355: 446-449.
17. Leid M, Kastner P, Lyons R et al. Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 1992; 68: 377-395.
18. Lehmann JM, Jong L, Fanjul A et al. Retinoids selective for retinoid X receptor response pathways. Science 1992; 258: 1944-1946.
19. Allenby G, Bocquel MT, Saunders M et al. Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci USA 1993; 90: 30-34.
20. Lufkin T, Lohnes D, Mark M et al. High postnatal lethality and testis degeneration in retinoic acid receptor α mutant mice. Proc Natl Acad Sci USA 1993; 90: 7225-7229.
21. Ghyselinck NB, Dupe V, Dierich A et al. Role of the retinoic acid receptor β (RARβ) during mouse development. Int J Dev Biol 1997; 41: 425-447.
22. Lohnes D, Kastner P, Dierich A, Mark M LeMeur M, Chambon P. Function of retinoic acid receptor γ in the mouse. Cell 1993; 73: 643-658.
23. Kastner P, Chan S. Function of RARα during the maturation of neutrophils. Oncogene 2001; 20: 7178-7185.
24. Ghosh J, Das S. A study on the effect of vitamin A deficiency and supplementation on tumorigenesis in mice. Neoplasma 1988; 35: 41-49.
25. Wolbach SB, Howe PR. Nutrition classics. J Exp Med 1925; 42: 753-777.
26. Hodges RE, Sauberlich HE, Canham JE et al. Hematopoietic studies in vitamin A deficiency. Am J Clin Nutr 1978; 31: 876-885.
27. Douer D, Koeffler HP. Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells. J Clin Invest 1982; 69: 277-283.
28. Gratas C, Menot ML, Dresch C, Chomienne C. Retinoid acid supports granulocytic but not erythroid diffrentiation of myeloid progenitors in normal bone marrow cells. Leukemia 1993; 7: 1156-1162.
29. Tocci A, Parolini I, Gabbianelli M et al. Dual action of retinoic acid on human embryonic/fetal hematopoiesis: blockade of primitive progenitor proliferation and shift from multipotent/erythroid/monocytic to granulocytic differentiation program. Blood 1996; 88: 2878-2888.
30. Zhu J, Heyworth CM, Glasow A et al. Lineage restriction of the RARα gene expression in myeloid differentiation. Blood 2001; 98: 2563-2567.
31. Labrecque J, Allan D, Chambon P, Iscove NN, Lohnes D, Hoang T. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors α1 and γ. Blood 1998; 92: 607-615.
32. Largman C, Detmer K, Corral JC, Hack FM, Lawrence HJ. Expression of retinoic acid receptor α mRNA in human leukemia cells. Blood 1989; 74: 99-102.
33. Kogan SC, Hong SH, Shultz DB, Privalsky ML, Bishop JM. Leukemia initiated by PMLRARα: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood 2000; 95: 1541-1550.
34. van Bockstaele DR, Lenjou M, Snoeck HW, Lardon F, Stryckmans P, Peetermans ME. Direct effects of 13-cis and all-trans retinoic acid on normal bone marrow (BM) progenitors: comparative study on BM mononuclear cells and on isolated CD34+BM cells. Ann Hematol 1993; 66: 61-66.
35. Labbaye C, Valtieri M, Testa U et al. Retinoic acid downmodulates erythroid differentiation and GATA1 expression in purified adultprogenitor culture. Blood 1994; 83: 651-656.
36. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995; 377: 454-457.
37. Horlein AJ, Naar AM, Heinzel T et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995; 377: 397-404.
38. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000; 14: 121-141.
39. Kastner P, Lawrence HJ, Waltzinger C, Ghyselinck NB, Chambon P, Chan S. Positive and negative regulation of granulopoiesis by endogenous RARα. Blood 2001; 97: 1314-1320.
40. Onodera M, Kunisada T, Nishikawa S, Sakiyama Y, Matsumoto S. Overexpression of retinoic acid receptor α suppresses myeloid cell differentiation at the promyelocyte stage. Oncogene 1995; 11: 1291-1298.
41. Tsai S, Bartelmez S, Heyman R, Damm K, Evans R, Collins SJ. A mutated retinoic acid receptor-α exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line. Genes Dev 1992; 6: 2258-2269.
42. Tsai S, Collins SJ. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proc Natl Acad Sci USA 1993; 90: 7153-7157.
43. Tsai S, Bartelmez S, Sitnicka E, Collins S. Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development. Genes Dev 1994; 8: 2831-2841.
44. Ruggero D, Wang ZG, Pandolfi PP. The puzzling multiple lives of PML and its role in the genesis of cancer. Bioessays 2000; 22: 827-835.
45. Borden KL. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol 2002; 22: 5259-5269.
46. Dyck JA, Maul GG, Miller Jr WH, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994; 76: 333-343.
47. Koken MH, Puvion-Dutilleul F, Guillemin MC et al. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994; 13: 1073-1083.
48. Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998; 17: 61-70.
49. LaMorte VJ, Dyck JA, Ochs RL, Evans RM. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc Natl Acad Sci USA 1998; 95: 4991-4996.
50. Borden KL, Boddy MN, Lally J et al. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. EMBO J 1995; 14: 1532-1541.
51. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP. Role of SUMO-1-modified PML in nuclear body formation. Blood 2000; 95: 2748-2752.
52. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J 2001; 20: 4547-4549.
53. Lang V, Zanchin NI, Lunsdorf H, Tuite M, McCarthy JE. Initiation factor eIF-4E of Saccharomyces cerevisiae. Distribution within the cell, binding to mRNA, and consequences of its overproduction. J Biol Chem 1994; 269: 6117-6123.
54. Lejbkowicz F, Goyer C, Darveau A, Neron S, Lemieux R, Sonenberg N. A fraction of the mRNA 5′ cap-binding protein, eukaryotic initiation factor 4E, localizes to the nucleus. Proc Natl Acad Sci USA 1992; 89: 9612-9616.
55. Strudwick S, Borden KL. The emerging roles of translation factor eIF4E in the nucleus. Differentiation 2002; 70: 10-22.
56. Negorev D, Maul GG. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 2001; 20: 7234-7242.
57. Lai HK, Borden KL. The promyelocytic leukemia (PML) protein suppresses cyclin DI protein production by altering the nuclear cytoplasmic distribution of cyclin DI mRNA. Oncogene 2000; 19: 1623-1634.
58. Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol 1994; 14: 6858-6867.
59. Wang ZG, Ruggero D, Ronchetti S et al. PML is essential for multiple apoptotic pathways. Nat Genet 1998; 20: 266-272.
60. Zhong S, Hu P, Ye TZ, Stan R, Ellis NA, Pandolfi PP. A role for PML and the nuclear body in genomic stability. Oncogene 1999; 18: 7941-7947.
61. Bischof O, Kim SH, Irving J, Beresten S, Ellis NA, Campisi J. Regulation and localization of the Bloom syndrome protein in response to DNA damage. J Cell Biol 2001; 153: 367-380.
62. Fogal V, Gostissa M, Sandy P et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 2000; 19: 6185-6195.
63. Guo A, Salomoni P, Luo J et al. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2000; 2: 730-736.
64. Torii S, Egan DA, Evans RA, Reed JC. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs. EMBO J 1999; 18: 6037-6049.
65. Zhong S, Salomoni P, Ronchetti S, Guo A, Ruggero D, Pandolfi PP. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med 2000; 191: 631-640.
66. Alcalay M, Tomassoni L, Colombo E et al. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol 1998; 18: 1084-1093.
67. Vallian S, Chin KV, Chang KS. The promyelocytic leukemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter. Mol Cell Biol. 1998; 18: 7147-7156.
68. Grande MA, van der Kraan I, van Steensel B et al. PML-containing nuclear bodies: their spatial distribution in relation to other nuclear components. J Cell Biochem 1996; 63: 280-291.
69. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-3215.
70. Rosenwald IB, Kaspar R, Rousseau D et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin DI at transcriptional and post-transcriptional levels. J Biol Chem 1995; 270:21176-21180.
71. Rousseau D, Kaspar R, Rosenwald I, Gehrke L, Sonenberg N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin DI mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci USA 1996; 93: 1065-1070.
72. Topisirovic I, Capili AD, Borden KL. Gamma interferon and cadmium treatments modulate eukaryotic initiation factor 4E-dependent mRNA transport of cyclin DI in a PML-dependent manner. Mol Cell Biol 2002; 22: 6183-6198.
73. Borden KL, Campbelldwyer EJ, Carlile GW, Djavani M, Salvato MS. Two RING finger proteins, the oncoprotein PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P proteins. J Virol 1998; 72: 3819-3826.
74. Boddy MN, Howe K, Etkin LD, Solomon E, Freemont PS. PIC I, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 1996; 13: 971-982.
75. Stadler M, Chelbi-Alix MK, Koken MH et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 1995; 11: 2565-2573.
76. Terris B, Baldin V, Dubois S et al. PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res 1995; 55:1590-1597.
77. Everett RD, Maul GG. HSV-1 1E protein Vmw1 10 causes redistribution of PML. EMBO J 1994; 13: 5062-5069.
78. Puvion-Dutilleul F, Chelbi-Alix MK, Koken M, Quignon F, Puvion E, de The H. Adenovirus infection induces rearrangements in the intranuclear distribution of the nuclear body-associated PML protein. Exp Cell Res 1995; 218: 9-16.
79. Carvalho T, Seeler JS, Ohman K et al. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J Cell Biol 1995; 131: 45-56.
80. Doucas V, Ishov AM, Romo A et al. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev 1996; 10: 196-207.
81. Turelli P, Doucas V, Craig E et al. Cytoplasmic recruitment of INII and PML on incoming HIV preintegration complexes: interference with early steps of viral replication. Mol Cell 2001; 7: 1245-1254.
82. Kelly C, Van Driel R, Wilkinson GW. Disruption of PML-associated nuclear bodies during human cytomegalovirus infection. J Gen Virol 1995; 76: 2887-2893.
83. Regad T, Chelbi-Alix MK. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 2001; 20: 7274-7286.
84. Reddy BA, Etkin LD. A unique bipartite cysteine-histidine motif defines a subfamily of potential zinc-finger proteins. Nucleic Acids Res 1991; 19: 6330.
85. Borden KL. RING domains: master builders of molecular scaffolds. J Mol Biol 2000; 295: 1103-1112.
86. Reid A, Gould A, Brand N et al. Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors. Blood 1995; 86: 4544-4552.
87. Lin RJ, Sternsdorf T, Tini M, Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001; 20: 7204-7215.
88. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARα gene in acute promyelocytic leukemia. Oncogene 2001; 20: 7186-7203.
89. Compton DA, Szilak I, Cleveland DW. Primary structure of NuMA, an intranuclear protein that defines a novel pathway for segregation of proteins at mitosis. J Cell Biol 1992; 116: 1395-1408.
90. Compton DA, Cleveland DW. NuMA, a nuclear protein involved in mitosis and nuclear reformation. Curr Opin Cell Biol 1994; 6: 343-346.
91. He D, Zeng C, Brinkley BR. Nuclear matrix proteins as structural and functional components of the mitotic apparatus. Int Rev Cytol 1995: 1-74.
92. Saredi A, Howard L, Compton DA. NuMA assembles into an extensive filamentous structure when expressed in the cell cytoplasm. J Cell Sci 1996; 109: 619-630.
93. Harborth J, Weber K, Osborn M. Epitope mapping and direct visualization of the parallel, in-register arrangement of the double-stranded coiled-coil in the NuMA protein. EMBO J 1995; 14: 2447-2460.
94. Yang CH, Lambie EJ, Snyder M. NuMA: an unusually long coiled-coil related protein in the mammalian nucleus. J Cell Biol 1992; 116: 1303-1317.
95. Szebeni A, Mehrotra B, Baumann A, Adam SA, Wingfield PT, Olson MO. Nucleolar protein B23 stimulates nuclear import of the HIV-1 Rev protein and NLS-conjugated albumin. Biochemistry 1997; 36: 3941-3949.
96. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1995; 267: 316-317.
97. Shiota M, Nakamura S, Ichinohasama R et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86: 1954-1960.
98. Yoneda-Kato N, Look AT, Kirstein MN et al. The t(3;5) (q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLFI. Oncogene 1996; 12: 265-275.
99. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
100. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002; 4: 529-533.
101. Grimwade D, Howe K, Langabeer S et al. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party. Br J Haematol 1996; 94: 557-573.
102. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990; 249: 1577-1580.
103. Longo L, Donti E, Mencarelli A et al. Mapping of chromosome 17 breakpoints; in acute myeloid leukemias. Oncogene 1990; 5: 1557-1563.
104. de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990; 347: 558-561.
105. Alcalay M, Zangrilli D, Pandolfi PP et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor α locus. Proc Natl Acad Sci USA 1991; 88: 1977-1981.
106. Reiter A, Saußele S, Grimwade D et al. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes, Chromosomes Cancer 2003; 36: 175-188.
107. Grimwade D. The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol 1999; 106: 591-613.
108. Pearson M, Carbone R, Sebastiani C et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406: 207-210.
109. Grignani F, Ferrucci PF, Testa U et al. The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74: 423-431.
110. Testa U, Grignani F, Barberi T et al. PML/RARα+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3. Cancer Res 1994; 54: 4508-4515.
111. Grignani F, Valtieri M, Gabbianelli M et al. PML/RARα fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood 2000; 96: 1531-1537.
112. Minucci S, Monestiroli S, Giavara S et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 2002; 100: 2989-2995.
113. He LZ, Tribioli C, Rivi R et al. Acute leukemia with promyelocytic features in PML/RARα transgenic mice. Proc Natl Acad Sci USA 1997; 94: 5302-5307.
114. Piazza F, Gurrieri C, Pandolfi PP. The theory of APL. Oncogene 2001; 20: 7216-7222.
115. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences. Blood 1997; 89: 376-387.
116. Brown D, Kogan S, Lagasse E et al. A PML-RARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 2551-2556.
117. He LZ, Guidez F, Tribioli C et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat Genet 1998; 18: 126-135.
118. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
119. Turhan AG, Lemoine FM, Debert C et al. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood 1995; 85: 2154-2161.
120. Grimwade D, Outram SV, Flora R et al. The T-lineage-affiliated CD2 gene lies within an open chromatin environment in acute promyelocytic leukemia cells. Cancer Res 2002; 62: 4730-4735.
121. Ferrucci PF, Grignani F, Pearson M, Fagioli M, Nicoletti I, Pelicci PG. Cell death induction by the acute promyelocytic leukemia-specific PML/RARα fusion protein. Proc Natl Acad Sci USA 1997; 94: 10901-10906.
122. Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ. A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia. Proc Natl Acad Sci USA 1999; 96: 15103-15108.
123. He LZ, Bhaumik M, Tribioli C et al. Two critical hits for promyelocytic leukemia. Mol Cell 2000; 6: 1131-1141.
124. He LZ, Merghoub T, Pandolfi PP. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene 1999; 18: 5278-5292.
125. Yeyati PL, Shaknovich R, Boterashvili S et al. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 1999; 18: 925-934.
126. Le Beau MM, Bitts S, Davis EM, Kogan SC. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood 2002; 99: 2985-2991.
127. Kelly LM, Kutok JL, Williams IR et al. PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002; 99: 8283-8288.
128. Kiyoi H, Naoe T, Yokota S et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997; 11: 1447-1752.
129. Kottaridis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
130. Schnittger S, Schoch C, Dugas M et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
131. Grignani F, De Matteis S, Nervi C et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-818.
132. Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811-814.
133. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91: 2634-2642.
134. Lin RJ, Evans RM, Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000; 5: 821-830.
135. Di Croce L, Raker VA, Corsaro M et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079-1082.
136. Chih DY, Chumakov AM, Park DJ, Silla AG, Koeffler HP. Modulation of mRNA expression of a novel human myeloid-selective CCAAT/enhancer binding protein gene (C/EBP epsilon. Blood 1997; 90: 2987-2994.
137. Liu TX, Zhang JW, Tao J et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 2000; 96: 1496-1504.
138. + acute pronyelocytic leukemia identified by small-array real-time PCR. Blood 2003; in press.
139. Matikainen S, Ronni T, Hurme M, Pine R, Julkunen I. Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood 1996; 88: 114-123.
140. Harada H, Kitagawa M, Tanaka N et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993; 259: 971-974.
141. Tanaka N, Ishihara M, Kitagawa M et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994; 77: 829-839.
142. Gianni M, Terao M, Fortino I et al. Stat 1 is induced and activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1997; 89: 1001-1012.
143. Liu M, Iavarone A, Freedman LP. Transcriptional activation of the human p21 (WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem 1996; 271: 31723-31728.
144. Bocchia M, Xu Q, Wesley U et al. Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells. Leuk Res 1997; 21: 439-447.
145. Weis K, Rambaud S, Lavau C et al. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell 1994; 76: 345-356.
146. Grimwade D, Gorman P, Duprez E et al. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 1997; 90: 4876-4885.
147. Hummel JL, Wells RA, Dube ID, Licht JD, Kamel-Reid S. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene 1999; 18: 633-641.
148. Grignani F, Testa U, Rogaia D et al. Effects on differentiation by the promyelocytic leukemia PML/RARα protein depend on the fusion of the PML protein dimerization and RARα DNA binding domains. EMBO J 1996; 15: 4949-4958.
149. Dong S, Tweardy DJ. Interactions of STAT5b-RARα, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 2002; 99: 2637-2646.
150. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19: 2474-2488.
151. Jansen JH, Mahfoudi A, Rambaud S, Lavau C, Wahli W, Dejean A. Multimeric complexes of the PML-retinoic acid receptor α fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways. Proc Natl Acad Sci USA 1995; 92: 7401-7405.
152. Pandolfi PP. PML, PLZF and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia. Haematologica 1996; 81: 472-482.
153. Zhu J, Lallenand-Breitenbach V, de Thé H. Pathways of retinoic acid or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission. Oncogene 2001; 20: 7257-7265.
154. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7: 680-686.
155. Ruchaud S, Duprez E, Gendron MC et al. Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc Natl Acad Sci USA 1994; 91: 8428-8432.
156. Duprez E, Benoit G, Flexor M, Lillehaug JR, Lanotte M. A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. Leukemia 2000; 14: 255-261.
157. Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller Jr WH. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood 1996; 88: 2671-2682.
158. Shao W, Benedetti L, Lamph WW, Nervi C, Miller Jr WH. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation. Blood 1997; 89: 4282-4289.
159. Kitamura K, Kiyoi H, Yoshida H, Saito H, Ohno R, Naoe T. Mutant AF-2 domain of PML-RARα in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARα and its down-regulation in acute promyelocytic leukemia. Leukemia 1997; 11: 1950-1956.
160. Imaizumi M, Suzuki H, Yoshinari M et al. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans-retinoic acid in acute promyelocytic leukemia. Blood 1998; 92: 374-382.
161. Ding W, Li YP, Nobile LM et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans-retinoic acid and intensive chemotherapy. Blood 1998; 92: 1172-1183.
162. Benoit G, Altucci L, Flexor M et al. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J 1999; 18: 7011-7018.
163. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759-767.
164. Murray CK, Estey E, Paietta E et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome. J Clin Oncol 1999; 17: 293-297.
165. Ferrara F, Morabito F, Martino B et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000; 18: 1295-1300.
166. Cassinat B, Chevret S, Zassadowski F et al. In vitro all-trans-retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. Blood 2001; 98: 2862-2864.
167. Tallman MS, Andersen JW, Schiffer CA et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-1028.
168. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-1200.
169. Asou N, Adachi K, Tamura J et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with alltrans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16: 78-85.
170. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131-4143.
171. Sanz MA, Lo Coco F, Martin G et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
172. Huang W, Sun GL, Li XS et al, Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 1993; 82: 1264-1269.
173. Vahdat L, Maslak P, Miller WH Jr et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-α isoform, and CD13 expression in patients treated with all-trans-retinoic acid. Blood 1994; 84: 3843-3849.
174. Gonzalez M, Barragan E, Bolufer P et al. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: a study of the PETHEMA group. Br J Haematol 2001; 114: 99-103.
175. Slack JL, Willman CL, Andersen JW et al. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARα isoform: results from intergroup protocol 0129. Blood 2000; 95: 398-403.
176. Gallagher RE, Li YP, Rao S et al. Characterization of acute promyelocytic leukemia cases with PML-RARα break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans-retinoic acid. Blood 1995; 86: 1540-1547.
177. Gu BW, Xiong H, Zhou Y et al. Variant-type PML-RAR (α) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron2 of the RAR (α) gene and identification of a new clinical subtype resistant to retinoic acid therapy. Proc Natl Acad Sci USA 2002; 99: 7640-7645
178. Gallagher RE, Willman CL, Slack JL et al. Association of PML-RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997; 90: 1656-1663.
179. Fenaux P, Chomienne C, Degos L. All-trans-retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13-25.
180. Warrell Jr RP. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood 1993; 82: 1949-1953.
181. Muindi JF, Young CW. Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans-retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Res 1993; 53: 1226-1229.
182. Kizaki M, Ueno H, Yamazoe Y et al. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood 1996; 87: 725-733.
183. Delva L, Cornic M, Balitrand N et al. Resistance to all-trans-retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993; 82: 2175-2181.
184. Zhou DC, Kim SH, Ding W, Schultz C, Warrell Jr RP, Gallagher RE. Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans-retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 2002; 99: 1356-1363.
185. Larson RS, Brown DC, Sklar LA. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood 1997; 90: 2747-2756.
186. Fenaux P, Le Deley MC, Castaigne S et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82: 3241-3249.
187. Mandelli F, Diverio D, Avvisati G et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined alltrans-retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di. Blood 1997; 90: 1014-1021.
188. Sanz MA, Martin G, Rayon C et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015-3021.
189. Paietta E, Andersen J, Racevskis J et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994; 8: 968-973.
190. Avvisati G, Lo Coco F, Diverio D et al. AIDA (all-trans-retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390-1398.
191. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans-retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia 1995; 9: 774-778.
192. Fenaux P, Chomienne C, Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol 1997; 24: 92-102.
193. Grimwade D, Walker H, Oliver F et al (on behalf of the Medical Research Council and Children's Leukaemia Working Parties). The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
194. Burnett AK, Goldstone AH, Stevens RM et al, Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700-708.
195. Burnett AK, Wheatley K, Goldstone AH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.
196. Specchia G, Lo Coco F, Vignetti M et al, Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans-retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol 2001; 19: 4023-4028.
197. Evans GD, Grimwade DJ. Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma 1999; 33: 219-229.
198. Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol 2001; 38: 26-36.
199. Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903.
200. Hong SH, Yang Z, Privalsky ML. Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor α oncoprotein found in human acute promyelocytic leukemia. Mol Cell Biol 2001; 21: 7172-7182.
201. Seeler JS, Dejean A, SUMO of branched proteins and nuclear bodies. Oncogene 2001; 20: 7243-7249.
202. Koken MH, Daniel MT, Gianni M et al, Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17) (q23;q21) APL patient. Oncogene 1999; 18: 1113-1118.
203. Kitamura K, Hoshi S, Koike M, Kiyoi H, Saito H, Naoe T. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans-retinoic acid. Br J Haematol 2000; 108: 696-702.
204. Soignet SL, Maslak P, Wang ZG et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
205. Muto A, Kizaki M, Kawamura C et al. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. Leukemia 2001; 15: 1176-1184.
206. Zhu Q, Zhang JW, Zhu HQ et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 2002; 99: 1014-1022.
207. Takayama N, Kizaki M, Hida T, Kinjo K, Ikeda Y. Novel mutation in the PML/RARα chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. Exp Hematol 2001; 29: 864-872.
208. Wang ZG, Rivi R, Delva L et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood 1998; 92: 1497-1504.
209. Davison K, Mann KK, Miller Jr WH. Arsenic trioxide: Mechanisms of action. Semin Hematol 2002; 39: 3-7.
210. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20: 7146-7153.
211. Shao W, Fanelli M, Ferrara FF et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124-133.
212. Gianni M, Koken MH, Chelbi-Alix MK et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998; 91: 4300-4310.
213. Cai X, Shen YL, Zhu Q et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262-270.
214. Chen GQ, Zhu J, Shi XG et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996; 88: 1052-1061.
215. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111.
216. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.
217. Sternsdorf T, Puccetti E, Jensen K et al. PIC-1/SUMO-1-modified PML-retinoic acid receptor α mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 1999; 19: 5170-5178.
218. Zhu XH, Shen YL, Jing YK et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 772-778.
219. Huang C, Ma WY, Li J, Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 1999; 59: 3053-3058.
220. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999; 59: 776-780.
221. Jiang XH, Wong BC, Yuen ST et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001; 91: 173-179.
222. Roboz GJ, Dias S, Lam G et al. Arsenic trioxide induces dose-and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530.
223. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860.
224. Camacho LH, Soignet SL, Chanel S et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000; 18: 2620-2625.
225. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
226. Huang CH, Chen WJ, Wu CC, Chen YC, Lee YT. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient. Pacing Clin Electrophysiol 1999; 22: 965-967.
227. Ohnishi K, Yoshida H, Shigeno K et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002; 16: 617-622.
228. Unnikrishnan D, Dutcher JP, Varshneya N et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97: 1514-1516.
229. Westervelt P, Brown RA, Adkins DR et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98: 266-271.
230. Lu DP, Qiu JY, Jiang B et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99: 3136-3143.
231. Zhao W, Wang H, Wang X et al. Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia. Thromb Res 2001; 102: 197-204.
232. Marasca R, Zucchini P, Galimberti S et al. Missense mutations in the PML/RARα ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Haematologica 1999; 84: 963-968.
233. Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol 2001; 66: 274-279.
234. Leoni F, Glanfaldoni G, Annunziata M et al. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica 2002; 87: 85-489.
235. Grimwade D, Walker H, Harrison G et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AMLII trial. Blood 2001; 98: 1312-1320.
236. Lallemand-Breitenbach V, Guillemin MC, Janin A et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043-1052.
237. Jurcic JG, Caron PC, Miller Jr WH et al. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans-retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 1995; 9: 244-248.
238. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000; 6: 372-380.
239. Paietta E, Andersen J, Gallagher R et al. The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia 1994; 8: 1108-1112.
240. Sainty D, Liso V, Cantu-Rajnoldi A et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Group Francais de Cytogenetique Hematologique, UK Cancer Cytogenetics Group and BIOMED I European Coomunity-Concerted Acion "Molecular Cytogenetic Diagnosis in Haematological Malignancies. Blood 2000; 96: 1287-1296.
241. Estey EH, Giles FJ, Beran M et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans-retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222-4224.
242. Petti MC, Pinazzi MB, Diverio D et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676. Br J Haematol 2001; 115: 63-65.
243. Giles FJ, Kantarjian HM, Korblau SM et al. Mylotarg (gemtuzunab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92: 406-413.
244. Estey EH, Giles FJ, Kantarjian H et al. Molecular remissions induced by liposomal-encapsulated all-trans-retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 2230-2235.
245. Douer D, Estey E, Santillana S et al. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans-retinoic acid. Blood 2001; 97: 73-80.
246. Tobita T, Takeshita A, Kitamura K et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans-retinoic acid. Blood 1997; 90: 967-973.
247. Miller Jr WH, Jakubowski A, Tong WP et al. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 1995; 85: 3021-3027.
248. Warrell Jr RP, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90: 1621-1625.
249. Cote S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller Jr WH. Altered ligand binding and transcriptional regulation by mutations in the PML/RARα ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood 2000; 96: 3200-3208.
250. Jing Y, Xia L, Waxman S. Targeted removal of PML-RARα protein is required prior to inhibition of histone deacetylase for overcoming all-trans-retinoic acid differentiation resistance in acute promyelocytic leukemia. Blood 2002; 100: 1008-1013.
251. Charrad RS, Li Y, Delpech B et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med 1999; 5: 669-676.
252. Charrad RS, Gadhoum Z, Qi J et al. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 2002; 99: 290-299.
253. Licht JD, Chomienne C, Goy A et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995; 85: 1083-1094.
254. Petti MC, Fazi F, Gentile M et al. Complete remission through blast cell differentiation in PLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood 2002; 100: 1065-1067.
255. Jansen JH, Lowenberg B. Acute promyelocytic leukemia with a PLZF-RARα fusion protein. Semin Hematol 2001; 38: 37-41.
256. Guidez F, Altucci L, Xu K et al. Rexinoid therapy bypasses the differentiation block associated with acute promyelocytic leukemia harboring the PLZF/RARα rearrangement. Blood 1998;(Suppl. 1): 766a [Abstract].
257. Culligan DJ, Stevenson D, Chee YL, Grimwade D. Acute promyelocytic leukaemia with t(11;17) (q23;q12-21) and a good initial response to prolonged ATRA and combination chemotherapy. Br J Haematol 1998; 100: 328-330.
258. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002; 16: 1959-1973.
259. Dyck JA, Warrell Jr RP, Evans RM, Miller Jr WH. Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-α protein. Blood 1995; 86: 862-867.
260. Hummel JL, Zhang T, Wells RA, Kamel-Reid S. The Retinoic acid receptor α (RARα) chimeric proteins PML-, PLZF-, NPM-, and NuMA-RARα have distinct intracellular localization patterns. Cell Growth Differ 2002; 13: 173-183.
261. Grimwade D. The significance of minimal residual disease in patients with t(15;17). Best Pract Res Clin Haematol 2002; 15: 137-158.
262. Lo Coco F, Diverio D, Pandolfi PP et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340: 1437-1438.
263. Diverio D, Rossi V, Avvisati G et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 1998; 92: 784-789.
264. Lo Coco F, Diverio D, Avvisati G et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225-2229.
265. Meloni G, Diverio D, Vignetti M et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene. Blood 1997; 90: 1321-1325.